Q4 2024 Earnings Call Transcript April 1, 2025 Operator: Good afternoon ladies and gentlemen and thank you for standing by.
CEO Cameron Reynolds highlighted 2024 as a pivotal year for VolitionRx, focusing on generating clinical data to establish the Nu.Q platform's role in oncology and sepsis. He emphasized 2025 goals of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback